Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for MGNX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -0.173M
March 31, 2026 -0.011M
December 31, 2025 -0.063M
September 30, 2025 0.00
June 30, 2025 -0.066M
March 31, 2025 0.00
December 31, 2024 -0.159M
September 30, 2024 -0.006M
June 30, 2024 -0.631M
March 31, 2024 -2.639M
December 31, 2023 -0.274M
September 30, 2023 -0.052M
June 30, 2023 -0.222M
March 31, 2023 -0.621M
December 31, 2022 -1.345M
September 30, 2022 -0.014M
June 30, 2022 -0.263M
March 31, 2022 -0.037M
December 31, 2021 0.763M
September 30, 2021 -20.43M
June 30, 2021 -2.452M
March 31, 2021 -100.66M
December 31, 2020 0.909M
September 30, 2020 -76.07M
June 30, 2020 -99.02M
Date Value
March 31, 2020 -0.162M
December 31, 2019 -0.297M
September 30, 2019 -0.037M
June 30, 2019 -0.633M
March 31, 2019 -119.00M
December 31, 2018 -0.475M
September 30, 2018 -0.132M
June 30, 2018 -103.76M
March 31, 2018 -0.629M
December 31, 2017 -0.359M
September 30, 2017 -1.147M
June 30, 2017 -33.73M
March 31, 2017 -0.108M
December 31, 2016 -0.492M
September 30, 2016 -1.011M
June 30, 2016 -0.127M
March 31, 2016 -0.224M
December 31, 2015 -0.25M
September 30, 2015 -140.98M
June 30, 2015 -0.17M
March 31, 2015 -62.95M
December 31, 2014 -0.222M
September 30, 2014 -0.18M
June 30, 2014 -0.2375M
March 31, 2014 -76.80M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 346.00M
Xencor, Inc. -1.031M
ACADIA Pharmaceuticals, Inc. -10.49M
Alnylam Pharmaceuticals, Inc. -33.56M
Anika Therapeutics, Inc. 0.643M